vimarsana.com

Page 43 - காப்புரிமை பெற்றது மருந்துகள் ஒழுங்குமுறைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intel Loses US Patent Trial, Ordered to Pay $2 18 Billion to VLSI Tech

US court rules in favour of AZ in Symbicort patent litigation

SoLVBL Solutions Inc Announces Filing of a Second U S Provisional Patent Application

SoLVBL Solutions Inc. Announces Filing of a Second U.S. Provisional Patent Application Toronto, Ontario (Newsfile Corp. - March 2, 2021) - SoLVBL Solutions Inc. (CSE: SOLV), an innovative cybersecurity company that provides proprietary data authentication SaaS that uniquely features advanced cryptography for data authentication at unprecedented speed and scalability, announced that the Company has a second patent pending with the United States Patent and Trademark Office. The application encompasses an adaption and optimization of a well-known and time-tested cryptographic algorithm, the algorithm has been adapted to reduce latency in data stream applications. Our ability to reinforce the intellectual property with these world s first patents around fast, low latency route to render arbitrary binary records effectively immutable in that they cannot be forged or altered without detection, means we have the legal framework now for protecting the leadership in this area, which we ha

Nascent Biotech Inc : Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

Nascent Biotech Inc.: Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ( Nascent Biotech , Nascent , or the Company ), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a Method-of-Use patent by the US Patent and Trademark Office ( USPTO ) for their primary asset, Pritumumab ( PTB ). Specifically, the patent approval is related to PTB s ability to cross the Blood-Brain Barrier ( BBB ). The recent patent allowance recognizes PTB s ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB.

eMagin Corporation: eMagin Awarded New Patent for dPd Direct Patterning OLED Microdisplay Technology

eMagin Corporation: eMagin Awarded New Patent for dPd Direct Patterning OLED Microdisplay Technology Proprietary Technology Supports State-of-the-Art OLED Displays Free of Brightness-reducing Color Filters HOPEWELL JUNCTION, NY / ACCESSWIRE / March 2, 2021 / eMagin Corporation, or the Company (NYSE American:EMAN), a leader in the development, design and manufacture of Active Matrix OLED microdisplays used in military and commercial AR/VR devices, and other near-eye imaging products, today announced it has been awarded a new patent by the U.S. Patent and Trademark Office (USPTO) for the Company s Direct Patterning Display (dPd) technology. The patent, number 10,903,427, which relates to the apparatus and method for direct patterning of an organic material using an electrostatic mask, follows two USPTO patents awarded last year and adds to eMagin s portfolio of 18 foundational dPd patents and utility applications for OLED patterning, processes and equipment.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.